CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"

Related Keywords

Mccormick Place ,Illinois ,United States ,Chicago ,American ,Phil Lhuilier ,Ignacio Melero Bermejo ,Catalym Gmb ,Alison Opalko ,Trophic Communications ,Oncology Congress ,American Society Of Clinical Oncology ,Ted Human Effector Cell Relocation Phase ,American Society ,Clinical Oncology ,Annual Meeting ,Growth Differentiation ,Presentation Details ,Universidad De Navarra ,Demand Mccormick Place ,Ted Human Effector ,Relocation Phase ,Phill Huilier ,Stephanie May ,Ihr Portfolio ,